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INTRODUCTION 
 
In 1971 president Richard Nixon declared a war on 
cancer and announced his goal to cure cancer by 1976, 
the bicentennial year.  Thirty nine years and more than 
100 billion dollars later, the cumulative adult death rate 
from cancer adjusted for the size and age of the 
population has improved by less than 5% [1].  In 
comparison, the death rate for heart disease over this 
time period has improved by more than 64% [1].  In 
2009, the NY Times published a series on the “war on 
cancer” specifically highlighting some of the suspected 
causes for these disappointing results.  The primary 
aim of the series was to investigate and discuss the 
translational research efforts over the past several 
decades and to explore some of the strategic decisions 
made by funding agencies as it relates to basic science 
and clinical research in order to move new therapies 
into the clinic quickly and safely.   
There is no simple explanation for why the death 
rate due to cancer hasn’t improved more than 5% over 
the past 4 decades. However, the progress made in 
treating pediatric cancer over the same time period may 
shed some light on ways to improve our approach to 
translational research in coming years. Today, the 
overall cure rate for pediatric cancers approaches 80%; 
this is a 30% improvement since 1971.  This is 
remarkable when we consider the rarity of pediatric 
cancer, the limited research funding and lack of 
investment by the pharmaceutical industry. Most of the 
progress in improving outcome for pediatric cancer has 
come  from clinical research. Indeed, the majority 
(>90%) of pediatric cancer patients are enrolled on 
treatment protocols and there is now abundant evidence 
that research protocols have helped optimize treatment 
intensification, drug dosing and timing, 
chemotherapeutic drug combination, and the 
identification of prognostic features of disease in 
relation to treatment plans. In sharp contrast, only 3% 
of adult cancer patients are enrolled on research 
protocols [2]. These numbers suggest that the advances 
in patient outcome for pediatric cancer since the 
beginning of the war on cancer can be attributed in part 




HISTORY OF PEDIATRIC CANCER CLINICAL 
RESEARCH 
 
The first pediatric cancer cooperative chemotherapy 
trials were initiated following congressional approval 
to increase monetary support for the study of cancer-
directed chemotherapy in the mid-1950s.  Initially 
these protocols focused on acute leukemia and later 
expanded to include brain tumors and solid tumors. 
Patients received chemotherapeutic agents that were 
shown to have anti-neoplastic properties in vitro or in 
adult patients. This approach has remained unchanged 
for the past 5 decades. In pediatric cancer clinical 
research, we still rely on poorly characterized in vitro 
and in vivo testing and Phase I, II and III results in 
adult patients. Initially, drugs were tested individually, 
but gradually the focus shifted to the evaluation of 
combination regimens as our understanding of single 
agent  drug resistance mechanisms improved. The 
current cooperative group of investigators is 
multidisciplinary in their approach.  They use 
preclinical findings to test new agents, develop novel 
therapeutic combinations, modify therapeutic 
schedules, monitor results of ongoing studies, develop 
patient registries and tissue banks for biological and 
genomic studies, provide statistical expertise for data 
analysis and ultimately establish standards of care for 
disease therapy. This careful and systematic clinical 
approach has been highly successful, increasing the 
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overall survival for pediatric leukemia from around 
10% in the1950’s to 80-90% today.    
 However, the dramatic improvement in overall 
survival may overshadow the significant challenges 
that lie ahead. Patients with high risk and/or rare 
pediatric cancers have had more limited improvements 
over the past several decades. Many in pediatric 
oncology are now coming to the conclusion that we 
have done as much as we can with existing therapies 
and drug dose intensification, schedules and other 
supportive clinical procedures such as autologous bone 
marrow transplants. Much of the current focus is now 
on biological studies, genomic studies and targeted 
therapies. Again, pediatric cancer is uniquely poised to 
benefit from these emerging approaches to translational 
research because of the long tradition of clinical and 
translational research.  
Eleven thousand children are diagnosed with cancer 
annually, which represents less than 1% of all new 
cancer diagnoses [3]. Among pediatric cancer patients, 
leukemia accounts for just over 30% of cases with the 
remainder split between brain tumors and solid tumors 
[3]. However, brain tumors and solid tumors are 
diverse, and the complexity of specific diagnoses 
further complicates clinical research. In addition, the 
limited number of patients can slow the pace of clinical 
research trials. The Children’s Oncology Group, a 
worldwide clinical trial cooperative group, runs the 
largest number of pediatric oncology protocols in the 
country. Even within this group, it takes a minimum of 
two years from the time of protocol conception and 
initial submission to protocol activation and another 3-
7 years to complete the trial. When data analysis is 
factored into the equation, it is not unusual for a 
clinical research study in pediatric cancer to span an 
entire decade.   
 While clinical trials have been essential in 
advancing the field of pediatric oncology, it is 
imperative that alternative methods are developed in 
conjunction with clinical research to improve patient 
survival.  Given the significant time lapse from the 
formulation of an idea to data accumulation, childhood 
cancers could benefit immensely from the use of 
thorough preclinical trials. There is a need to 
understand the basic molecular, biologic and 
developmental pathways that lead to formation of these 
rare tumors.   Further, this understanding is essential 
for the development of targeted anticancer agents that 
will translate into increased overall survival for 
pediatric malignancies. Preclinical testing and biology 
studies have had little impact on childhood cancer 
patient outcome over the past 5 decades but with the 
shift toward molecular targeted agents, these efforts 
have now moved to the forefront of the battle for 
children’s lives in the war on cancer. Retinoblastoma is 
one example of successful translation of laboratory-
based research discoveries into new clinical trials and 
provides us with a model as we tackle the challenges 
that lie ahead in the war on cancer. 
 
 
3 PILLARS OF SUCCESSFUL PEDIATRIC 
CANCER TRANSLATIONAL RESEARCH 
PROGRAM 
 
The most important consideration for moving new 
drugs into clinical trials as a result of laboratory-based 
research is open communication between laboratory 
investigators and clinical researchers. Without this vital 
partnership, even the most promising preclinical 
research studies may never advance to the clinic. 
Indeed, retinoblastoma represents one such example. 
Despite decades of research on the RB1 gene and Rb 
pathway, laboratory based research has had little 
impact on the clinical management of the disease until 
recently. While open communication is an essential 
foundation for a translational research program, it is 
not sufficient. There are 3 disciplines that are essential 
for a successful laboratory based research program—
preclinical animal models, pharmacology and chemical 
biology. When these 3 disciplines are integrated into in 
a disease-specific translational research team and 
partnered with clinical investigators, a tremendous 
amount of progress can be made in a short amount of 
time with relatively limited resources.   
 
 
PRECLINICAL ANIMAL MODELS 
 
  Preclinical animal models that recapitulate the 
molecular, cellular and genetic features of the human 
disease are an important starting point for translational 
research. With recent advances in genetic engineering 
in mice, it is now possible to delete tumor suppressor 
genes or ectopically express oncogenes in a variety of 
cellular lineages during development. This has led to 
the development of a series of preclinical mouse 
models for rhabdomyosarcoma, osteosarcoma, 
neuroblastoma and retinoblastoma among the pediatric 
solid tumors. Clearly, the genetic lesions that occur in 
the human tumor should be recapitulated as closely as 
possible in the mouse model.   
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A high level of N-myc expression is one of the 
hallmarks of aggressive neuroblastoma in children. To 
model this feature of neuroblastoma in children, the 
tyrosine hydroxylase promoter was used to drive 
ectopic N-myc expression in the trunk neural crest 
lineage that populates the adrenal and paraspinal 
ganglia [4]. These tumors appear to originate in the 
adrenal or para-adrenal space and mimic many of the 
features of childhood neuroblastoma. However, even if 
the genetic lesions are similar to the human disease, 
this does not necessarily mean that the animal model 
faithfully recapitulates the human disease. One must 
also consider the cell biology, molecular signature of 
the tumors and disease progression. For example, one 
of the hallmarks of neuroblastoma is catecholamine 
production and urine catecholamine levels are used as a 
diagnostic test for patients with neuroblastoma. Using 
transmission electron microscopy combined with cell 
biology, it has been shown that the mouse 
neuroblastomas are indeed catecholinergic based on the 
presence of dense core vesicles [4]. However, to date, 
there has not been an unbiased molecular comparison 
of mouse neuroblastoma to human neuroblastoma and 
this is important because the mouse tumors do not 
metastasize at the same frequency or sites as the human 
disease. Therefore, while neuroblastoma represents a 
very good example of a mouse model of the human 
disease, there are still several questions about the 
mouse tumors in comparison to the human disease that 
need to be answered. As preclinical testing programs 
gain prominence and are more widely used for testing 
new targeted agents, it is important to consider all of 
the aspects of the human disease not just the initiating 
genetic lesions.  
  With a well-characterized mouse model in hand, 
the next step is to perform the preclinical testing using 
the same diagnostics and functional assessments that 
are used clinically for that patient population. It is not 
appropriate to administer chemotherapy in preclinical 
models of pediatric cancer and use metrics for efficacy 
that have no parallel in the clinical setting. Fortunately, 
most if not all of the tests that are used clinically, are 
now available for preclinical testing including MRI, 
PET, CT, ultrasound and a variety of more specialized 
metrics that are used for specific cancer types. These 
advances in diagnostic imaging and functional 
assessment tests in rodents provide unprecedented 
opportunities to perform comprehensive preclinical 
testing. Moreover, when combined with the dose and 
schedule of chemotherapy that is used in patients, it 
can provide the predictive power that is lacking from 
the extensively used flank xenografts in 
immunocompromised mice. We suggest that 
comprehensive preclinical testing is not only possible 
for the first time, using sophisticated genetically 
engineered mouse models of human cancer, but that it 
is essential to have predictive power for understanding 
which new combinations of chemotherapy tested in the 
lab will have the best chance of success in the clinic. In 
this way, one of the greatest challenges in pediatric 
cancer (limited patient population), provides us with a 
tremendous opportunity to take full advantage of 
laboratory developments in mouse models and 
diagnostic tools for translational research. 
 
   
CHEMICAL BIOLOGY 
 
  Several academic research institutes and 
medical centers now support high-throughput screening 
infrastructure and chemical biology. Clearly, the goal 
of such facilities is very different from similar units in 
pharmaceutical companies but many researchers 
interested in translational medicine are starting to use 
high throughput screening for drug discovery and drug 
development. In many ways, drug discovery and drug 
development efforts in academia are complementary to 
efforts in industry. The reason for this is that academic 
researchers often select targets and research projects 
for very different reasons than the large pharmaceutical 
companies. An academic researcher may pick a 
particular target and/or cancer subtype based on the 
opportunity to shed light on fundamental biological 
processes in order to advance our understanding of 
cancer. In contrast, pharmaceutical companies must 
weigh very different factors in selecting particular drug 
targets and disease populations—not the least of which 
is market share. Moreover, the deeper understanding of 
the fundamental biological processes being targeted 
clearly reside in academic labs while the expertise in 
toxicity, pharmacology, drug formulation and drug 
development lies within industry. We envision a 
partnership that combines the best of academic 
chemical biology and therapeutics with the strength of 
the pharmaceutical industry. 
  There are several advantages of such a system. 
If the high throughput screening and chemical biology 
efforts at an academic center are run like a mid-size 
pharmaceutical company in terms of quality control, 
data collection, data analysis, and standardized assays 
used to measure solubility, permeability, toxicity and 
stability then these data can be directly transferred to  
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industry when the time comes for further development 
as a clinical candidate. In general, both groups are 
seeking the same shared goal to understand if a 
particular chemical compound targets the desired 
protein or pathway and if this has efficacy in cellular 
and preclinical models. Other important considerations 
are the options for clinical formulations, off-target 
effects, and export from cells by drug transporters. If a 
particular compound moves forward to the point that it 
is a reasonable candidate then  the pharmaceutical 
industry has all of the expertise and infrastructure to 
formulate and produce the compound using a GMP 
facility and they will also perform the appropriate 
toxicity studies by partnering with a GLP provider. 
Most of the larger pharmaceutical companies have 
extensive networks around the globe to bring new 
agents into Phase I and II trials and academic centers 
cannot match that infrastructure. Looking forward in an 
era of molecular targeted therapy for cancer, 
partnerships between industry and academia that takes 
advantage of their unique strengths will most likely 
have the greatest impact on improving the outcome for 
cancer patients. This is particularly true for pediatric 
cancer with the exception of clinical trials 
infrastructure. Because  pediatric cancers are rare, 
pharmaceutical companies have overlooked this patient 
population and clinical trials would have to be part of 
more academic clinical research efforts in the context 





Virtually all oncology drugs are developed for the 
adult cancer population and are then re-formatted for 
pediatric use. This involves more than a simple dose-
reduction for the smaller subject. Volume of 
distribution, gastric absorption, liver and renal 
clearance, and enzymes utilized for metabolism of 
drugs vary by age across the pediatric population.   
Thus, great care must be taken when calculating and 
applying a human pediatric drug dose from a clinically 
relevant adult dose. While proper determination of 
drug doses can be complicated within the same species, 
it can be an incredible challenge and burden between 
species.  For decades scientists have addressed this 
problem by using species-specific conversion factors, 
based purely on weight and body surface area, to 
determine relevant interspecies dosages [5]. The FDA 
has a dosage calculator published on line to aid in 
calculating relevant doses.  However, drug metabolism 
and clearance are species specific. Additionally, the 
liver, kidneys and hematopoietic  system between 
species may have significant differences in their 
sensitivity to chemotherapeutic agents. None of these 
factors are taken into account with the use of the 
species-specific dose calculations. Therefore, a more 
appropriate dosing method should be used to determine 
interspecies doses, specifically one that relies on 
comprehensive pharmacokinetic and pharmacodynamic 
studies in which the area under the curve (AUC) is 
determined for each individual drug over time within a 
species and then directly applied to the other species. 
The advantage to using the species-specific 
conversion factor is that it is quick and does not require 
labor and time intensive pharmacokinetic studies. 
Additionally, this conversion factor can occasionally 
yield an equivalent drug dose as determined by AUC 
guided dosing. For example a common pediatric dose 
of vincristine is 1.5mg/m2. With the aid of the species-
specific conversion factor the equivalent adult mouse 
dose is 0.5mg/kg. This is very similar to the determined 
dose  when using pharmacokinetic studies. In 2002, 
Groninger and colleagues evaluated the 
pharmacokinetics of vincristine in children diagnosed 
with ALL and determined that the median AUC for a 
dose of 1.5mg/m2 was 0.12uMxh [6]. In 1999 
Thompson et al studied the pharmacokinetics of 
1mg/kg vincristine in rodents and determined the AUC 
was 0.32uMxh [7]. Thus, given the linear relationships, 
the equivalent mouse dose calculated for a human dose 
of 1.5mg/m2 is equal to 0.4mg/kg.  This drug dose is 
very similar to the dose of 0.5mg/kg achieved by using 
the species-specific calculator. 
However, there are numerous examples in which 
the species-specific conversion dose varies 
significantly from the AUC guided dose and/or far 
exceeds the animal’s maximum tolerated dose. One 
such example is carboplatin dosing. A typical 
carboplatin dose used in pediatrics is 560mg/m2. With 
the aid of the species-specific conversion factor the 
equivalent adult mouse dose is 187mg/kg. However, 
this dose is higher than the LD10 for a mouse [8] and is 
simply not tolerated. Using the pharmacokinetic works 
of Newell and VanHennik published on data obtained 
from children and mice, the equivalent mouse dose for 
a pediatric dose of 560mg/m2 is 80mg/kg [9,10]. This 
dose is less than half of the dose calculated using the 
species specific calculator. 
A detailed understanding of the metabolism and 
clearance of drugs is essential for proper dosing in 
children as well as the unique physiology of organs  
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involved in metabolism and clearance. More 
importantly,  potential toxicities associated with the 
pediatric population must also be considered and tested 
in juvenile animal studies prior to clinical trials. For 
example, hedgehog pathway inhibitors were tested in 
juvenile rodents and found to have profound toxicities 
that were developmental stage specific. The current 
clinical trials with hedgehog inhibitors in the pediatric 
population of medulloblastoma patients are focused on 
older patients in an effort to minimize these devastating 
developmental defects (ClinicalTrials.gov Identifier: 
NCT00939484). While developmental pathways such 
as Notch and Hedgehog provide attractive targets for 
pediatric cancer, the broad systemic toxicities may 
prove to be too detrimental because of the importance 
of these pathways in normal development and tissue 
homeostasis. 
It is also essential to use pharmacokinetics to 
identify the appropriate dose and schedule for the 
preclinical studies. Historically, the vast majority of 
preclinical studies in rodents for pediatric cancer used 
doses and schedules of drug administration that were 
not clinically relevant. 
The process of translating preclinical rodent 
toxicology trials into pediatric clinical protocols has 
relied upon a number of retrospective reviews in which 
one-tenth of the mouse LD10 (reported as mg/m2) was 
found to represent a safe phase I trial starting dose 
[5,11,12,13,14]. However, these preclinical animal 
trials all relied on single-dose or single course (i.e. 
daily x 5 days) administration of a drug. Performing 
toxicology studies over 2-4 weeks or up to 2 courses in 
order to check the safety of a proposed starting phase I 
trial starting dose when given by repeated 
administration is recommended by the Committee for 
Proprietary Medicinal Products (CPMP) prior to 
starting a phase I clinical trial. However, this minimal 
expansion cannot compare to the lengthy exposure and 
duration of treatment required in pediatric trials. 
Further expansion with repeated dosing that mirrors a 
clinical trial (up to six months) is only required for 
Phase II, Phase III or Marketing Applications [15]. In 
addition to the limited duration of study in mouse 
models, these drugs are most often tested as single 
agents. While information on the efficacy of a new 
drug is important, drugs are most often given in 
combination in the clinical setting. Potential synergy or 
even antagonistic effects of multi-drug combinations 
are of vital importance when considering 
implementation of a new pediatric clinical trial.  
In some cases, initiation of phase I trials at one-
tenth the mouse MTD/LD10  would have exceeded the 
human MTD (fludarabine [16],tallimustine [17]). On 
the other hand, starting with too conservative a dose 
can result in lengthy dose escalation and delays in 
further therapeutic trials, as well as the unnecessary use 
of clinical resources and large number of patients 
treated with doses that are not therapeutic. A review in 
1999 compared 25 cytotoxic chemotherapeutic 
compounds tested in preclinical murine toxicology 
studies and later in clinical phase I trials [18]. In 20 
drugs where DLT was observed at the human MAD, 
the ratio of the human MAD to mouse MTD/LD10 was 
2.6 (range 0.2-16) and the number of dose escalations 
required to reach a MAD or DLT was 8 (range 3-19) 
[18]. In 2010, LeTourneau et al reviewed the literature 
supporting the choice of starting dose for molecularly 
targeted agents and found that, while the dose used in 
phase I trials was overall safe, the section was based on 
diverse practices and a wide variety of toxicologic 
parameters without any standardization [19]. In 
addition, the authors commented that the non-
hematologic DTL common in molecularly targeted 
agents may not be readily predictable with basic 
pharmacology data alone due to off-target effects. 
These reviews highlight the variability of inter-species 
response to chemotherapeutic agents. Even the 
expansive Pediatric Preclinical Testing Program 
launched in the early 2000s to identify new agents for 
therapy in pediatric cancer has focused on testing 
single agents in short duration dosing schedules [20]. 
There is a clearly apparent need for the integration of 
pharmacokinetic and pharmacodynamic investigations 
with expanded preclinical toxicology studies, both in 
terms of duration of therapy and use of multi-agent 
combination therapy.  
Currently, most chemotherapeutic regimens utilize 
complex combinations of drugs. Therefore it is 
important to also consider how these drugs interact 
with respect to toxicities and drug absorption and 
clearance. We have shown previously that the 
combination of topotecan and carboplatin was more 
effective than the standard of care in preclinical models 
of retinoblastoma [21]. However, these two drugs 
cannot be administered concurrently by the systemic 
route of administration because of their overlapping 
toxicity profiles. In this case, local delivery of one 
agent by subconjunctival injection is the preferred 
route of drug delivery because the tumor cells will be 
exposed to both drugs simultaneously but the systemic 
exposure of the drug delivered by subconjunctival  
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injection is low enough to mitigate systemic toxicities 
normally associated with the combination 
chemotherapy. Solid tumor patients would benefit 






There have been truly remarkable advances in our 
understanding of cancer genetics and cancer biology 
over the past four decades since Nixon declared the 
war on cancer. In addition, there has been progress in 
development of new drugs for cancer therapy and 
complementary efforts in advancing our understanding 
of cancer etiology, environmental factors, biomarkers 
and cancer screening. Each of these battles in isolation 
can be viewed as victories. Further advances in 
biology, genetics, cancer diagnostics, biomarker 
development and clinical research will clearly continue 
to impact patient outcome but without better 
integration across clinical research and laboratory 
research questions may remain about where we stand 
in the war on cancer. 
Even with more limited resources, little investment 
from the pharmaceutical industry and a small patient 
population, children with cancer have fared much 
better in the war on cancer. One reason for this has 
been the focus on a well-coordinated multidisciplinary 
approach to clinical research. However, clinical 
research is not enough to continue on this trajectory for 
pediatric cancer. It would be a mistake to assume that 
the same strategy will continue to reap the benefits 
over the next several decades. Most of the oncology 
drugs in clinical development are targeted therapies. 
Our ability to match molecular targeted agents to 
particular cancers and stages of disease and to combine 
them effectively with broad-spectrum chemotherapy 
relies on outstanding biology studies and preclinical 
testing combined with chemical biology and 
pharmacology—the 3 essential pillars of a successful 
translational research program. This is true for 
pediatric cancer and adult cancer. By building on the 
tradition of coordinated clinical research and focusing 
our efforts to bridge the gap between clinical research 
and laboratory based translational research we may be 
able to make progress towards winning the war on 
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